Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
The Korea Institute Of Radiological & Medical Sciences has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners across 2 distinct art units. This distribution suggests that while the examiners are unique for each action, there is overlap in the art units assigned to the portfolio. The presence of the distinct art units for the 3 pending actions implies that multiple actions are being reviewed within the same specialized group.
TAYLOR V OH is the busiest examiner for the institute, with 1 pending office action. This is 1 of the total pending actions. Because there are 3 distinct examiners for the workload, no single examiner is responsible for all of the institute's cases. The concentration of the portfolio within the Biotechnology & Pharmaceuticals technology area highlights the institute's research focus. The overlap in art units despite the variety of examiners suggests a concentration of technical subject matter. This environment allows for some familiarity with the institute's technology within the specific groups at the patent office. Practitioners can leverage this concentration while managing the assigned examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
| ANDERSON, JAMES D | 1 | 55.1% | +19.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864544 | COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF ERK INHIBITOR | OH, TAYLOR V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16955699 | USE FOR PROTECTING OR MITIGATING RADIATION DAMAGE, AND FOR PREVENTING OR TREATING PULMONARY FIBROSIS | ANDERSON, JAMES D | 103d overdue |
| 18027639 | BIOMARKER COMPOSITION FOR PREDICTING PROGNOSIS OF BRAIN DISEASES CAUSED BY MICROPLASTIC EXPOSURE AND METHOD FOR PREDICTING PROGNOSIS USING SAME | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16955699 | USE FOR PROTECTING OR MITIGATING RADIATION DAMAGE, AND FOR PREVENTING OR TREATING PULMONARY FIBROSIS | ANDERSON, JAMES D | 103d overdue |
| 18864544 | COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF ERK INHIBITOR | OH, TAYLOR V | — |
| 18027639 | BIOMARKER COMPOSITION FOR PREDICTING PROGNOSIS OF BRAIN DISEASES CAUSED BY MICROPLASTIC EXPOSURE AND METHOD FOR PREDICTING PROGNOSIS USING SAME | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18864544 | COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF ERK INHIBITOR | OH, TAYLOR V | — | §112 | Non-Final OA | — | Pending | Nov 10, 2024 |
| 18027639 | BIOMARKER COMPOSITION FOR PREDICTING PROGNOSIS OF BRAIN DISEASES CAUSED BY MICROPLASTIC EXPOSURE AND METHOD FOR PREDICTING PROGNOSIS USING SAME | GOLDBERG, JEANINE ANNE | 1682 | §101§112 | Non-Final OA | — | Pending | Mar 22, 2023 |
| 16955699 | USE FOR PROTECTING OR MITIGATING RADIATION DAMAGE, AND FOR PREVENTING OR TREATING PULMONARY FIBROSIS | ANDERSON, JAMES D | 1629 | §102§103§112 | Non-Final OA | 103d overdue | Pending | Sep 29, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial